Navigation Links
MediciNova Announces Positive Clinical Results From MN-166 Phase II,Multiple Sclerosis Trial

Conference Call to Discuss Results On Thursday, March 29, 2007, At 2:00 p.m. Pacific Time

SAN DIEGO, March 27, 2007 (PRIME NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company that is publicly traded on the Nasdaq Global Market (Nasdaq:MNOV) and the Hercules Market of the Osaka Securities Exchange (Code Number:4875), today announced positive clinical findings from the 12-month core period of a Phase II clinical trial of MN-166 that measures both surrogate (radiological) and clinical outcomes over two years of treatment in 297 patients with relapsing multiple sclerosis (MS).

The randomized, double-blind, placebo-controlled trial showed a significant increase in the proportion of patients who remained relapse-free over the first 12 months of treatment with 60 mg per day of MN-166 compared to placebo (p=0.03). The time to first relapse was also significantly increased in patients treated with 60 mg of MN-166 per day compared to placebo (p=0.04). Positive trends were also observed in the annualized relapse rate (p=0.08) and number of relapses (p=0.10) among patients who completed the full first 12 months of treatment with 60 mg of MN-166 per day compared to those patients completing the first 12 months of treatment on placebo.

A significant reduction in brain volume loss (p=0.04), as measured by cranial magnetic resonance imaging (MRI) scans, was observed in patients treated with 60 mg per day of MN-166 compared to placebo. Loss of brain volume on MRI has been shown to correlate with clinical progression and disability in MS patients. Positive trends were also observed in several other radiological outcome measures, including the volume of gadolinium-enhancing (T1) lesions (p=0.09) in patients treated with 60 mg of MN-166 per day compared with placebo. However, no reduction in the cumulative number of active (gadolinium-enhancing (T1) and non-enhancing new/enlarging (T2)) lesions on crani
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
2. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
3. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
4. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
5. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
8. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
9. Protox Announces Positive Clinical Data from Prostate Cancer Study
10. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
11. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
Post Your Comments:
(Date:3/2/2015)... 2015  DURECT Corporation (Nasdaq: DRRX ) ... December 31, 2014. Total revenues were $4.3 million for ... the three months ended December 31, 2013.  Net loss ... 31, 2014 as compared to a net loss of ... were $19.4 million and net loss was $22.1 million ...
(Date:3/2/2015)... Therapeutics, Inc. (NASDAQ: HALO ) today reported financial results ... 2014. Financial highlights for the fourth quarter include revenues of ... $0.04 per share. This compares to revenues of $12.5 million ... share, for the fourth quarter of 2013. Financial highlights for ... a net loss of $68.4 million, or $0.56 per share. ...
(Date:3/2/2015)... Biomedical, Inc., a leading processor of human tissue, synthetics, ... it hired Lou Barnes as President and ... formed UMTB Biomedical as a wholly-owned subsidiary to acquire ... 2014. UMTB is the oldest tissue bank in the ... veteran of the tissue banking industry, having most recently ...
Breaking Medicine Technology:DURECT Corporation Announces Fourth Quarter 2014 Financial Results and Update of Programs 2DURECT Corporation Announces Fourth Quarter 2014 Financial Results and Update of Programs 3DURECT Corporation Announces Fourth Quarter 2014 Financial Results and Update of Programs 4DURECT Corporation Announces Fourth Quarter 2014 Financial Results and Update of Programs 5DURECT Corporation Announces Fourth Quarter 2014 Financial Results and Update of Programs 6DURECT Corporation Announces Fourth Quarter 2014 Financial Results and Update of Programs 7DURECT Corporation Announces Fourth Quarter 2014 Financial Results and Update of Programs 8DURECT Corporation Announces Fourth Quarter 2014 Financial Results and Update of Programs 9DURECT Corporation Announces Fourth Quarter 2014 Financial Results and Update of Programs 10DURECT Corporation Announces Fourth Quarter 2014 Financial Results and Update of Programs 11DURECT Corporation Announces Fourth Quarter 2014 Financial Results and Update of Programs 12Halozyme Reports Fourth Quarter And Full Year 2014 Financial Results 2Halozyme Reports Fourth Quarter And Full Year 2014 Financial Results 3Halozyme Reports Fourth Quarter And Full Year 2014 Financial Results 4Halozyme Reports Fourth Quarter And Full Year 2014 Financial Results 5Halozyme Reports Fourth Quarter And Full Year 2014 Financial Results 6Halozyme Reports Fourth Quarter And Full Year 2014 Financial Results 7Halozyme Reports Fourth Quarter And Full Year 2014 Financial Results 8Halozyme Reports Fourth Quarter And Full Year 2014 Financial Results 9Vivex Biomedical, Inc. Announces New Chief Operating Officer of Tissue Bank 2Vivex Biomedical, Inc. Announces New Chief Operating Officer of Tissue Bank 3
... Cobalis Corp. (Pink Sheets: CLSC ... provide investors and shareholders with further details and the latest ... issues. Shareholders and investors MUST RSVP to participate ... 2010 at 1:15pm Pacific Time. Interested parties may RSVP to ...
... (Nasdaq: GNBT, www.generex.com ), the leader in drug ... the mouth, today announced that it has been awarded ... Intellectual Property Office granted Canadian Patent No. 2,401,942, a ... This new patent increases the number of ...
Cached Medicine Technology:Cobalis Corp. Announces Second Update Conference Call for Investors on October 5, 2010 2Generex Awarded a New Patent in Canada for its Proprietary Buccal Drug Delivery System 2Generex Awarded a New Patent in Canada for its Proprietary Buccal Drug Delivery System 3
(Date:3/2/2015)... Clearwater, FL (PRWEB) March 02, 2015 ... comply with Title VI of the Civil Rights Act, ... (LEP) and hearing loss are bringing light to the ... Bureau statistics reveal that nearly 1 in 20 U.S. ... 1 in 10 in some major cities.(1) Stratus ...
(Date:3/2/2015)... (PRWEB) March 02, 2015 Doctors in ... be a better predictor of outcomes for people with ... read details of the new study on the ... at the University of Eastern Piedmont followed the cases ... pleurodesis treatment for excess lung fluid. , “Persistent ...
(Date:3/2/2015)... Gummy smile reduction expert, Dr. ... can involve one or several procedures to reduce the appearance ... for a more even gum line. Dr. Farnoosh is the ... that can permanently lighten discolored or naturally dark gums. ... a personalized treatment plan to address a patient’s specific needs ...
(Date:3/2/2015)... 2015 After a rigorous evaluation process ... pricing and long-term strategy, Blood Centers of America (BCA) ... for member centers’ testing needs. , BCA, which comprises ... than 30 percent of the U.S. blood supply, made ... is committed to drive cost savings to members,” said ...
(Date:3/2/2015)... 2015 New York singer/songwriter Richie ... delivering a plenary address entitled Finding the Music ... of Healing and Recovery at this year’s National ... Executive Summit (BHES).     , With more than 300 ... been recorded by some of the biggest names ...
Breaking Medicine News(10 mins):Health News:Stratus Video Addresses Inadequate Language Interpreting for 2.4 Million U.S. Children 2Health News:Stratus Video Addresses Inadequate Language Interpreting for 2.4 Million U.S. Children 3Health News:Stratus Video Addresses Inadequate Language Interpreting for 2.4 Million U.S. Children 4Health News:New Research Links Talc Treatment Response with Mesothelioma Prognosis, According to Surviving Mesothelioma 2Health News:Gummy Smile Expert, Dr. Alex Farnoosh, is Now Offering Gum Reshaping Procedures 2Health News:Blood Centers of America Chooses QualTex Laboratories as Vendor of Choice 2Health News:Blood Centers of America Chooses QualTex Laboratories as Vendor of Choice 3Health News:Richie Supa Announced as a Plenary Speaker at NCAD 2015 2
... afflicting as many as 3.4% of all adults. Like other ... to society, often leading to suicide, job loss, and criminal ... become worse over time. Scientists have found that ... this disorder in the short term, including Naltrexone, used to ...
... from Boston University School of Medicine (BUSM) have ... robotic-assisted radical prostatectomy (RARP) is considerably different when ... an open prostatectomy (OP). These findings, which are ... RARP and OP surgery, may have implications for ...
... therapy can completely eradicate some models of cancer, according ... published in the current issue of the British ... from the University of Hull and ETH Zurich ... vessels. When irradiated with light, the molecules create particles ...
... thinking and reasoning abilities of adults who survived childhood ... Survivor Study. Researchers hope the findings will lead to ... population. The work was led by St. Jude Children,s ... to show that childhood cancer survivors are particularly vulnerable ...
... 11, 2011 In a first-of-its-kind study with nuts, ... (ARS) of the United States Department of Agriculture (USDA) ... absorbed by the body. The findings indicate that ... originally thought further validating pistachios as one of ...
... April 10 (HealthDay News) -- An "organic" label on foods ... healthier and tastier, new research suggests. The study included ... were conventionally and organically produced chocolate sandwich cookies, plain yogurt ... but they were labeled as either "regular" or "organic." ...
Cached Medicine News:Health News:In it to win it? 2Health News:Researchers find anatomic differences after robotic-assisted radical prostatectomy 2Health News:Light, chemistry, action -- a new technique to target skin cancers? 2Health News:Fatigue and sleep woes worsen neurocognitive problems in childhood cancer survivors 2Health News:Fatigue and sleep woes worsen neurocognitive problems in childhood cancer survivors 3Health News:Pistachios deliver weight management support, heart health benefits 2Health News:'Organic' Label Seems to Make Food Taste Better 2
Are you looking for an inexpensive, effective Blood and Infusion Warmer? , ,Animec is an economical fluid warmer that uses standard I.V. tubing instead of special disposable sets....
... and easy-to-use solution that's perfectly suited to ... ,Symeon's light weight and mobility mean that ... working position. It can also be easily ... "spaghetti syndrome" is minimized through the use ...
... 6400 Series anesthesia workstation provides an ... are combined to provide true clinical ... State of the art computer technology ... a single color touchscreen display panel. ...
... used in facilities where space is a ... and gas delivery technologies with an ergonomic ... the functionality of the Draeger Infinity patient ... a workplace environment that is a sound ...
Medicine Products: